NEW YORK (GenomeWeb) – Canadian firm LexaGene Holdings said today that it has closed a non-brokered private placement under which it raised gross proceeds of about C$2 million ($1.5 million).

The company sold 6.7 million units of common stock at C$.30 per unit. Each unit consisted of one common share and one common share purchase warrant, which entitles the holder to acquire an additional common share for C$.60 per share within a three-year period. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.